▶ EPITALON · SUBTOPIC · SAFETY PROFILE

EPITALON Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of EPITALON.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of EPITALON. Severity, frequency, and attribution depend on the source publication.

• Very limited Western safety data
• No serious adverse events reported in Russian literature at standard doses

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for EPITALON.

• Largely unstudied in Western literature

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for EPITALON in the published record:

• Active malignancy (theoretical · telomerase activation may interact with cancer biology · NOT validated)

FDA REGULATORY STATUS

Not FDA-approved. Research-use only in the United States.

WADA REGULATORY STATUS

Not currently listed on the WADA Prohibited List.

OTHER JURISDICTIONS

Russia · Registered as research and clinical-research compound by the Institute of Bioregulation and Gerontology.

SAFETY Q+A FROM LITERATURE

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

• Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett 2002. PMID 12624353. link
• Khavinson V, et al.. Effects of pineal peptide preparation Epithalamin on free-radical processes in humans and animals. Neuro Endocrinol Lett 2003. PMID 14523389. link

RELATED PAGES

▶ LAST UPDATED · 2026-05-19